NCOG-06. PREDICTING TUMOR TREATING FIELD COMPLIANCE USING NEUROCOGNITIVE TESTING

Of the 12 patients, 10 were male and the median age was 64 years. ECOG performance status was 0 or 1 in all patients. Nine initiated TTFields therapy, and we followed their TTField use and compliance. We reviewed the mean score on each of the neurocognitive tests in TTField users and non-users and found no significant difference. We also analyzed the means of the TTField users and compared those who had a compliance of > 75% versus 0–75%. In this comparison, we found that patients who had a compliance of > 75% trended towards better neurocognitive function in 2 of the tests, the Trailmaking Test A (TMTA) and the Test of Premorbid Function (TOPF). The TMTA is a measure of simple visual-motor processing speed and visual attention, and the TOPF represents an estimation of the patients premorbid intellectual abilities. The mean TMTA z-scores were -3.40 in patients who had a compliance of > 75% and -0.943 those with compliance of 0–75% (p=0.080). The mean TOPF standard scores were 108 in patients with compliance > 75% compared to 88.7 in those with a compliance of 0–75% (p=0.062). CONCLUSIONS: Neurocognitive testing may be used a potential predictor of TTField compliance. In our small patient population, those with higher premorbid intelligence and faster psychomotor speed tended to have better compliance in TTField use. We expect that further investigation, in a larger dataset, may lead to a more refined neurocognitive profile of TTField compliance.